Apararenone

Apararenone (INN) (developmental code name MT-3995) is a nonsteroidal antimineralocorticoid which is under development by Mitsubishi Tanabe Pharma for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis.[1][2][3] It was also previously being developed for the treatment of hypertension, but development was discontinued for this indication.[1] Apararenone acts as a highly selective antagonist of the mineralocorticoid receptor (Ki < 50 nM), the receptor for aldosterone.[1][2][3] As of 2017, it is in phase II clinical trials.[1]

Apararenone
Clinical data
Other namesMT-3995
Routes of
administration		Oral
Drug classAntimineralocorticoid
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC17H17FN2O4S
Molar mass364.391 g/mol g·mol−1
3D model (JSmol)

See also

References
  1. http://adisinsight.springer.com/drugs/800032686
  2. Yang J, Young MJ (2016). "Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences". Curr Opin Pharmacol. 27: 78–85. doi:10.1016/j.coph.2016.02.005. PMID 26939027.
  3. Kolkhof P, Nowack C, Eitner F (2015). "Nonsteroidal antagonists of the mineralocorticoid receptor". Curr. Opin. Nephrol. Hypertens. 24 (5): 417–24. doi:10.1097/MNH.0000000000000147. PMID 26083526.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.